8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Feb 27, 2026·SEC
IN8bio, Inc.(INAB)Earnings, Financials & Key Ratios
INAB•NASDAQ
$1.39
Price updated Jul 7, 2026
AboutIN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$17M+37.5%
- Net Income-$19M+36.1%
- EPS (Diluted)-4.44-678.9%
- ROE-92.49%+40.1%
INAB Price & Volume
IN8bio, Inc. (INAB) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Capital Runway Sustainability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial liquidity constraints
Key Thesis Takeaways
- IN8bio remains in a high-risk pre-revenue stage, characterized by a heavy reliance on external capital to fund its specialized cell therapy pipeline.
- While management has successfully reduced quarterly R&D expenditures from $5.2 million in 2024Q2 to $2.6 million in 2026Q1, the lack of commercial revenue streams leaves the company vulnerable to significant dilution.
- Investors should monitor the company's ability to extend its $21.9 million cash position, as current operational losses continue to erode the balance sheet.
Verdict Logic
the company's precarious liquidity position, evidenced by a cash balance that declined to $21.9 million in 2026Q1, suggests a high probability of dilutive financing in the near term.
INAB Growth Metrics
IN8bio, Inc. (INAB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM30.79%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-481.89%
Return on Capital
10 Years-95.08%
5 Years-92.16%
3 Years-108.54%
Last Year-84.55%
Peers Comparison
Key metrics vs top competitors for IN8bio, Inc. (INAB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.39 | $6.44M | -0.31 | — | — | -92.49% | — | |
| $3.02 | $352.01M | -2.63 | -51.24% | -2056.79% | -58.89% | — | |
| $1.35 | $171.71M | -1.21 | 14.85% | -173.02% | — | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — | |
| $60.77 | $5.86B | -9.39 | -89.97% | -13856.54% | -30.88% | — |
Compare INAB vs Peers
IN8bio, Inc. (INAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INAB SEC Filings & Documents
IN8bio, Inc. (INAB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when INAB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
INAB Frequently Asked Questions
IN8bio, Inc. (INAB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is INAB profitable?
IN8bio, Inc. (INAB) reported a net loss of $19.0M for fiscal year 2025.
Dividend & Returns
What is INAB's return on equity?
IN8bio, Inc. (INAB) has a return on equity (ROE) of -92.5%. Negative ROE indicates the company is unprofitable.
What is IN8bio, Inc.'s free cash flow?
IN8bio, Inc. (INAB) had negative free cash flow of $14.5M in fiscal year 2025, likely due to heavy capital investments.